Peptides / Immune and antimicrobial

Synthetic analog · 9 amino acids · 1,439.8 Da

LTX-315

LTX-315, also called ruxotemitide, is an experimental oncolytic peptide injected directly into tumors, in phase 2 trials for solid tumors and not approved. Studies in people tested it on immune response and tumor growth, and tracked side effects. PepBank shows 18 results on LTX-315 from 3 studies in people, and 124 from animal and lab studies. The strongest evidence is a trial in people without random groups. Data as of 2026-10-30.

Also known as LTX 315, VP-315, VP-LTX-315, Ruxotemitide, Oncopore

9 amino acids, from first to lastKKWWKKWXK

Evidence level: Mostly animal studies124 of 142 results come from studies in animals and lab cells. 3 studies in people.

Results in people

13% of 142 results

Results in animals

35% of 142 results

Results in lab cells

52% of 142 results

From computer models

0% of 142 results

Overview

LTX-315 at a glance

What it is	Synthetic analog, 9 amino acids
Approval	Regulatory status not recorded
In sport	Status unknown
Studies	38 studies with results. 25 of them gave LTX-315, with 142 results. 18 in people50 in animals74 in lab cells
Best study in people	Non-randomized trial with 39 people (2021)
Clinical trials	7 registered: 1 active or planned, 3 with posted results

The science

What is LTX-315?

An oncolytic peptide studied by direct injection into tumors.

Amino acids in one chain

The history of LTX-315

2010January
A registered trial of LTX-315 started (NCT01058616).
2014
The oldest paper on LTX-315 in PepBank is from 2014.

LTX-315 structure and chemistry

The key facts about the molecule. Long codes are in the closed section below.

Sequence, 9 amino acidsFrom the first amino acid to the last

+K1+KWW+K5+KWX+K

Darker means more water-repelling+ and − show charge in the bodyOutlined: changed amino acid

Structure

LTX-315 is a synthetic analog of 9 amino acids, with no ring, 2 changed amino acids.

Formula

C₇₈H₁₀₆N₁₈O₉

Molecular weight

1,439.8 g/mol

CAS number

1345407-05-7

Development

Lytix Biopharma. Highest phase: phase 2.

Identifiers

PubChem 46200994, ChEMBL CHEMBL4297628, UNII 75FBL12IZ7, DrugBank DB12748

Full sequence, SMILES and InChIKey

Three-letter sequence
Lys-Lys-Trp-Trp-Lys-Lys-Trp-Dip-Lys-NH2

InChIKey
GGAKLYWEFZCVIT-TVEKFXMRSA-N

SMILES
C1=CC=C(C=C1)C(C2=CC=CC=C2)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC5=CNC6=CC=CC=C65)NC(=O)[C@H](CC7=CNC8=CC=CC=C87)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)N

See charge, composition and 3D structure on the Scientific page

The evidence

What LTX-315 studies show

Results grouped by what the studies measured. Each card shows where its results come from.

Mostly animal studies124 of 142 results come from studies in animals and lab cells. 3 studies in people.

Immune system and inflammation

54 results · 7 in people · 29 animal · 18 lab

In patients with solid tumors, biopsies showed CD8+ T-cell entry into tumors after LTX‑315 treatment. Clinical cancer research, 2021

Top results

In patients with solid tumors, biopsies showed CD8+ T-cell entry into tumors after LTX‑315 treatment. (Clinical cancer research, 2021)
In mice, LTX‑315 increased IL1β. (Cancer immunology, immunotherapy, 2014)
In a woman with a desmoid tumor, LTX‑315 treatment increased CD8+ immune cells in the tumor. (Journal of medical case reports, 2019)

Cancer

32 results · 5 in people · 15 animal · 12 lab

In patients with solid tumors, biopsies showed tumor tissue death after LTX‑315 treatment. Clinical cancer research, 2021

Top results

In patients with solid tumors, biopsies showed tumor tissue death after LTX‑315 treatment. (Clinical cancer research, 2021)
In a woman with a desmoid tumor, disease remained stable long term after LTX‑315 treatment. (Journal of medical case reports, 2019)
In patients with solid tumors, 29% had injected tumors shrink by at least 30% after LTX‑315. (Clinical cancer research, 2021)

Pain

1 result · 1 in people

In a woman with a desmoid tumor, symptoms gradually improved after LTX‑315 treatment. Journal of medical case reports, 2019

Top results

In a woman with a desmoid tumor, symptoms gradually improved after LTX‑315 treatment. (Journal of medical case reports, 2019)

Infections

7 results · 1 animal · 6 lab

In mice, LTX‑315 showed activity against drug-resistant and highly virulent Klebsiella pneumoniae. Journal of advanced research, 2025

Top results

In mice, LTX‑315 showed activity against drug-resistant and highly virulent Klebsiella pneumoniae. (Journal of advanced research, 2025)
In lab tests, LTX‑315 inhibited reference bacteria at 8-32 μM. (Journal of peptide science, 2026)
In lab tests, LTX‑315 killed gram-positive pathogens, including drug-resistant strains. (Journal of advanced research, 2025)

Survival and serious illness

1 result · 1 animal

In mice with mammary carcinomas, NK-cell depletion weakened survival extension with LTX‑315. Oncoimmunology, 2021

Top results

In mice with mammary carcinomas, NK-cell depletion weakened survival extension with LTX‑315. (Oncoimmunology, 2021)

Cells, genes and aging

8 results · 8 lab

In cells, LTX‑315 reduced the electrical potential across human melanoma cell mitochondrial membranes. Oncotarget, 2015

Top results

In cells, LTX‑315 reduced the electrical potential across human melanoma cell mitochondrial membranes. (Oncotarget, 2015)
In cells, LTX‑315 immediately stopped mitochondrial respiration. (Oncotarget, 2015)
In cells, LTX‑315 significantly altered the detailed structure of human melanoma cell mitochondria. (Oncotarget, 2015)

All 3 studies in people

In people

In patients with solid tumors, biopsies showed CD8+ T-cell entry into tumors after LTX‑315 treatment.

2021Clinical cancer research39 people

In people

In a woman with a desmoid tumor, LTX‑315 treatment increased CD8+ immune cells in the tumor.

2019Journal of medical case reports1 person

In people

In melanoma and sarcoma patients, LTX‑315 treatment was followed by CD8+ immune cell infiltration.

2019Cell stress

All 38 LTX-315 studies by area Open the Scientific page

Key LTX-315 studies

Studies in people come first, then studies in animals and in the lab.

People
Safety, Antitumor Activity, and T-cell Responses in a Dose-Ranging Phase I Trial of the Oncolytic Peptide LTX-315 in Patients with Solid Tumors
Spicer et al. 2021 · Clinical cancer research : an official journal of the American Association for Cancer Research · 39 people · cited by 63
12 results
People
Enhanced T-lymphocyte infiltration in a desmoid tumor of the thoracic wall in a young woman treated with intratumoral injections of the oncolytic peptide LTX-315: a case report
Jebsen et al. 2019 · Journal of medical case reports · 1 person · cited by 14
5 results
People
LTX-315 sequentially promotes lymphocyte-independent and lymphocyte-dependent antitumor effects
Liao et al. 2019 · Cell stress · cited by 27
8 results
Animals
The oncolytic peptide LTX-315 triggers immunogenic cell death
Zhou et al. 2016 · Cell death & disease · cited by 119
9 results
Animals
Complete regression and systemic protective immune responses obtained in B16 melanomas after treatment with LTX-315
Camilio et al. 2014 · Cancer immunology, immunotherapy : CII · cited by 78
9 results

All 38 LTX-315 studies

LTX-315 clinical trials

ClinicalTrials.gov lists 7 trials of LTX-315. 1 is active or planned, and 3 have posted results. PepBank does not show trial results.

Solid bars are dates that happened. Hatched bars are planned dates. Data from ClinicalTrials.gov.

Open-Label Proof of Concept Study of VP-315 in Basal Cell Carcinoma

Phase 2completed92 people

Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Advanced Melanoma

Phase 2completed23 people

LTX-315 and Adoptive T-cell Therapy in Advanced Soft Tissue Sarcoma (ATLAS-IT-04)

Phase 2completed6 people

All 4 LTX-315 trials

Status and safety

Is LTX-315 approved?

FDA

United States

Status unknown

Status unknown.

EMA

European Union

Status unknown

Status unknown.

WADA

Sport

Not recorded

Status unknown.

Regulatory status not recorded. Status unknown.

Laws and labels change, so check the regulator for the current status.

LTX-315 side effects and safety

PepBank has 6 safety results from studies of LTX-315. 5 of them come from studies in people.

Safety results from studies (6)

In patients with solid tumors, transient low blood pressure occurred in 46% during LTX‑315 treatment. (Clinical cancer research, 2021)
In a woman with a desmoid tumor, LTX‑315 treatment was stopped in week 16 after a serious allergic reaction. (Journal of medical case reports, 2019)
In patients with solid tumors, flushing occurred in 28% during LTX‑315 treatment. (Clinical cancer research, 2021)
In patients with solid tumors, injection site reactions occurred in 38% during LTX‑315 treatment. (Clinical cancer research, 2021)
In patients with solid tumors, severe hypersensitivity or anaphylaxis occurred in 10% during LTX‑315 treatment. (Clinical cancer research, 2021)
In lab tests, LTX‑315 breakdown produced nontoxic metabolites. (Journal of medicinal chemistry, 2016)

See every safety result on the Scientific page

Doses studied (3 shown)

The doses that these studies used. They are not recommendations.

Dose as reported	Class	Species	Route	Duration	Design	Source
4 mg	Animal	rabbit	Not reported	Not reported	Study in live animals	Zhou 2022
2 mg	Animal	rabbit	Not reported	Not reported	Study in live animals	Zhou 2022
10 and 20 µmol/L	Lab	Not reported	Not reported	Not reported	Study on cells in a dish	Ma 2021

Questions and more

Ask a question about LTX-315

The answer links to every study it uses.

What does the evidence say about LTX-315?Is LTX-315 tested in people?Compare with Thymosin alpha-1 Compare with Thymulin (serum thymic factor)

Sources

Database: PepBank data for LTX-315 (data version 308560)
Regulator: FDA status record
Regulator: EMA status record
Regulator: WADA status record
Trial registry: ClinicalTrials.gov

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Ask your AI about LTX-315

Curo is a peptide shop. PepBank and Curo have the same owner. See the Curo catalog (opens in a new tab).

LTX-315

LTX-315 at a glance